EGFR and neoplasm: In NSCLC patients with high PD-L1 expression (>50%), EGFR-TKI targeted therapy-induced an increased expression of CD73 in tumor cells compared to baseline and might explain, in part, the poor efficacy obtained in some patients in response to ICI targeting programmed death 1 (PD1) on T cells [124].